PDCD1 and neoplasm: PR were seen in 3 of 4 patients with a tumor type that was FDA approved for nivolumab monotherapy, and benefit was observed in 5 patients bearing tumors that did not have approval for anti–PD-1 agents (1 PR and 4 SD).